We thank Gang Lv and colleagues for the response to our study.1 We agree that minimal residual disease (MRD) monitoring could help to optimise the treatment of mantle-cell lymphoma with ibrutinib and other Bruton tyrosine kinase (BTK) inhibitors. However, no study comparing outcomes of continuous use of BTK inhibitors versus an MRD-driven approach has yet been reported.